4//SEC Filing
KAKKIS EMIL D 4
Accession 0000950170-24-026625
CIK 0001515673other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:06 PM ET
Size
11.4 KB
Accession
0000950170-24-026625
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO10% Owner
Transactions
- Award
Common Stock
2024-03-01+38,428→ 578,198 total - Tax Payment
Common Stock
2024-03-01$53.69/sh−17,417$935,119→ 560,781 total - Award
Common Stock
2024-03-01+3,132→ 563,913 total - Award
Stock Option (Right to Buy)
2024-03-01+70,094→ 70,094 totalExercise: $53.69Exp: 2034-03-01→ Common Stock (70,094 underlying)
Holdings
- 2,263,985(indirect: See FN)
Common Stock
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F3]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
- [F4]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F5]By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001248093
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:06 PM ET
- Size
- 11.4 KB